{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:55:56Z","timestamp":1792756556436,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.cld.2020.06.001","type":"journal-article","created":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T23:35:52Z","timestamp":1597534552000},"page":"535-547","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["The Changing Global Epidemiology of Hepatocellular Carcinoma"],"prefix":"10.1016","volume":"24","author":[{"given":"Allyce","family":"Caines","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranya","family":"Selim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Salgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2020.06.001_bib1","first-page":"1","article-title":"Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis","volume":"16","author":"Ghouri","year":"2017","journal-title":"J\u00a0Carcinog"},{"issue":"5","key":"10.1016\/j.cld.2020.06.001_bib2","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.cld.2020.06.001_bib3","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/j.gastro.2018.08.065","article-title":"Epidemiology and management of hepatocellular carcinoma","volume":"156","author":"Kulik","year":"2019","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.cld.2020.06.001_bib4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.7603\/s40730-016-0041-5","article-title":"Incidence and mortality of liver cancer and their relationship with the human development index in the world","volume":"3","author":"Arabsalmani","year":"2016","journal-title":"Biomed Res Ther"},{"issue":"10","key":"10.1016\/j.cld.2020.06.001_bib5","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1002\/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J","article-title":"Hepatitis B virus. The major etiology of hepatocellular carcinoma","volume":"61","author":"Beasley","year":"1988","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.cld.2020.06.001_bib6","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ajpath.2013.10.028","article-title":"The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy","volume":"184","author":"Knudsen","year":"2014","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1016\/j.cld.2020.06.001_bib7","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/hep.28123","article-title":"Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009","volume":"62","author":"Younossi","year":"2015","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2020.06.001_bib8","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jhep.2018.10.008","article-title":"Hepatocellular carcinoma in the setting of alcohol-related liver disease","volume":"70","author":"Ganne-Carri\u00e9","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2020.06.001_bib9","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1289\/ehp.0901388","article-title":"Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment","volume":"118","author":"Liu","year":"2010","journal-title":"Environ Health Perspect"},{"issue":"8b","key":"10.1016\/j.cld.2020.06.001_bib10","first-page":"13","article-title":"Towards the elimination of hepatitis B and hepatocellular carcinoma","volume":"108","author":"Spearman","year":"2018","journal-title":"South Afr Med J"},{"key":"10.1016\/j.cld.2020.06.001_bib11","author":"World Health Organization"},{"issue":"9859","key":"10.1016\/j.cld.2020.06.001_bib12","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.cld.2020.06.001_bib13","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jhep.2019.08.025","article-title":"Epidemiology and surveillance for hepatocellular carcinoma: new trends","volume":"72","author":"Singal","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2020.06.001_bib14","author":"World Health Organization"},{"issue":"12","key":"10.1016\/j.cld.2020.06.001_bib15","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","article-title":"The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015","volume":"3","author":"Akinyemiju","year":"2017","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.cld.2020.06.001_bib16","first-page":"899","article-title":"Epidemiology and management of hepatocellular carcinoma","volume":"24","author":"Yang","year":"2010","journal-title":"Infect Dis Clin"},{"issue":"3\u20134","key":"10.1016\/j.cld.2020.06.001_bib17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000360947","article-title":"Genotypes and genetic variability of hepatitis B virus","volume":"57","author":"Kramvis","year":"2014","journal-title":"Intervirology"},{"issue":"1","key":"10.1016\/j.cld.2020.06.001_bib18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000347209","article-title":"Direct effects of hepatitis B virus-encoded proteins and chronic infection in liver cancer development","volume":"31","author":"Ringelhan","year":"2013","journal-title":"Dig Dis"},{"issue":"11","key":"10.1016\/j.cld.2020.06.001_bib19","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jama.1996.03540110060032","article-title":"Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan","volume":"276","author":"Chen","year":"1996","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.cld.2020.06.001_bib20","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1001\/jama.1988.03410150079034","article-title":"Efficacy of a mass hepatitis B vaccination program in Taiwan: studies on 3464 infants of hepatitis B surface antigen\u2014carrier mothers","volume":"260","author":"Hsu","year":"1988","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.cld.2020.06.001_bib21","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1053\/j.gastro.2016.05.048","article-title":"Long-term effects of hepatitis B immunization of infants in preventing liver cancer","volume":"151","author":"Chang","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2020.06.001_bib22","doi-asserted-by":"crossref","first-page":"18035","DOI":"10.1038\/nrdp.2018.35","article-title":"Hepatitis B virus infection","volume":"4","author":"Yuen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"Suppl 3","key":"10.1016\/j.cld.2020.06.001_bib23","first-page":"18","article-title":"Is hepatitis B birth dose vaccine needed in Africa?","volume":"27","author":"Tamandjou","year":"2017","journal-title":"Pan Afr Med J"},{"issue":"2","key":"10.1016\/j.cld.2020.06.001_bib24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S2468-1253(18)30270-X","article-title":"Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission","volume":"4","author":"Cooke","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"02","key":"10.1016\/j.cld.2020.06.001_bib25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S2468-1253(16)30161-3","article-title":"Africa Network for Gastrointestinal and Liver Diseases. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa liver cancer consortium","volume":"2","author":"Yang","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Suppl","key":"10.1016\/j.cld.2020.06.001_bib26","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/0264-410X(90)90209-5","article-title":"Hepatitis B: global importance and need for control","volume":"8","author":"Maynard","year":"1990","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.cld.2020.06.001_bib27","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/hep.27034","article-title":"Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice","volume":"60","author":"Zhang","year":"2014","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2020.06.001_bib28","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0168-8278(05)80494-5","article-title":"Failure of neonatal hepatitis B vaccination: the role of HBV-DNA levels in hepatitis B carrier mothers and HLA antigens in neonates","volume":"20","author":"del Canho","year":"1994","journal-title":"J\u00a0Hepatol"},{"issue":"24","key":"10.1016\/j.cld.2020.06.001_bib29","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa1508660","article-title":"Tenofovir to prevent hepatitis B transmission in mothers with high viral load","volume":"374","author":"Pan","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.cld.2020.06.001_bib30","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1515\/hsz-2017-0118","article-title":"Chronic viral hepatitis and its association with liver cancer","volume":"398","author":"Tu","year":"2017","journal-title":"Biol Chem"},{"issue":"2","key":"10.1016\/j.cld.2020.06.001_bib31","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jhepr.2019.05.001","article-title":"The oncogenic role of hepatitis delta virus in hepatocellular carcinoma","volume":"1","author":"Puigveh\u00ed","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cld.2020.06.001_bib32","series-title":"Global hepatitis report 2017","author":"WHO","year":"2017"},{"issue":"6","key":"10.1016\/j.cld.2020.06.001_bib33","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease","volume":"155","author":"Kanwal","year":"2018","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2020.06.001_bib34","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1159\/000235677","article-title":"Non-alcoholic fatty liver disease in older people","volume":"55","author":"Frith","year":"2009","journal-title":"Gerontology"},{"issue":"1","key":"10.1016\/j.cld.2020.06.001_bib35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/ijmr.IJMR_1456_17","article-title":"Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: an increasing concern","volume":"149","author":"Dhamija","year":"2019","journal-title":"Indian J Med Res"},{"issue":"5","key":"10.1016\/j.cld.2020.06.001_bib36","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/hep.23594","article-title":"Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection","volume":"51","author":"Starley","year":"2010","journal-title":"Hepatology"},{"issue":"47","key":"10.1016\/j.cld.2020.06.001_bib37","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.3748\/wjg.v23.i47.8263","article-title":"Clinical epidemiology and disease burden of nonalcoholic fatty liver disease","volume":"23","author":"Perumpail","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"12","key":"10.1016\/j.cld.2020.06.001_bib38","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cgh.2012.10.001","article-title":"Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review","volume":"10","author":"White","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2020.06.001_bib39","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \"hits\"?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2020.06.001_bib40","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.cld.2020.06.001_bib41","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3390\/ijms17091575","article-title":"Molecular pathogenesis of NASH","volume":"17","author":"Caligiuri","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.cld.2020.06.001_bib42","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/hep.22734","article-title":"Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis","volume":"49","author":"Paradis","year":"2009","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.cld.2020.06.001_bib43","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.5858\/132.11.1761","article-title":"Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?","volume":"132","author":"Guzman","year":"2008","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1016\/j.cld.2020.06.001_bib44","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.gastro.2015.03.044","article-title":"Obesity early in adulthood increases risk but does not affect outcomes of hepatocellular carcinoma","volume":"149","author":"Hassan","year":"2015","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2020.06.001_bib45","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.jhep.2011.10.027","article-title":"Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace","volume":"56","author":"Baffy","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2020.06.001_bib46","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/aje\/155.4.323","article-title":"Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women","volume":"155","author":"Donato","year":"2002","journal-title":"Am J Epidemiol"},{"issue":"7","key":"10.1016\/j.cld.2020.06.001_bib47","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","article-title":"Hepatocellular carcinoma: epidemiology and molecular carcinogenesis","volume":"132","author":"El\u2013Serag","year":"2007","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.cld.2020.06.001_bib48","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/cncr.30559","article-title":"Hepatitis C virus infection and the risk of cancer among elderly US adults: a registry-based case-control study","volume":"123","author":"Mahale","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.cld.2020.06.001_bib49","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s15010-019-01345-y","article-title":"Epidemiological and etiological variations in hepatocellular carcinoma","volume":"48","author":"Sagnelli","year":"2020","journal-title":"Infection"},{"issue":"3","key":"10.1016\/j.cld.2020.06.001_bib50","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Blach","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"13","key":"10.1016\/j.cld.2020.06.001_bib51","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"5 Pt 1","key":"10.1016\/j.cld.2020.06.001_bib52","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","article-title":"Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies","volume":"158","author":"Morgan","year":"2013","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.cld.2020.06.001_bib53","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2020.06.001_bib54","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1055\/s-0039-3399566","article-title":"Epidemiology of Liver Cancer in Africa: Current and Future Trends","volume":"40","author":"Okeke","year":"2020","journal-title":"Semin Liver Dis"},{"issue":"6","key":"10.1016\/j.cld.2020.06.001_bib55","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1002\/hep.29707","article-title":"The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: an ERCHIVES study","volume":"67","author":"Li","year":"2018","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2020.06.001_bib56","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2019.07.040","article-title":"Direct-acting antiviral therapy for hepatitis C virus infection is associated with increased survival in patients with a history of hepatocellular carcinoma","volume":"157","author":"Singal","year":"2019","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2020.06.001_bib57","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.gastro.2008.09.014","article-title":"Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease","volume":"136","author":"Lok","year":"2009","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2020.06.001_bib58","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.23744","article-title":"Outcome of sustained virological responders with histologically advanced chronic hepatitis C","volume":"52","author":"Morgan","year":"2010","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2020.06.001_bib59","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2020.06.001_bib60","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 4","key":"10.1016\/j.cld.2020.06.001_bib61","doi-asserted-by":"crossref","first-page":"iv238","DOI":"10.1093\/annonc\/mdy308","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Vogel","year":"2018","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.cld.2020.06.001_bib62","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.cgh.2018.12.018","article-title":"Cost effectiveness of hepatocellular carcinoma surveillance after a sustained virologic response to therapy in patients with hepatitis C virus infection and advanced fibrosis","volume":"17","author":"Farhang Zangneh","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2020.06.001_bib63","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.30823","article-title":"Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"issue":"43","key":"10.1016\/j.cld.2020.06.001_bib64","first-page":"1487","article-title":"Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008","volume":"60","author":"Centers for Disease Control and Prevention (CDC)","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"10.1016\/j.cld.2020.06.001_bib65","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMsa1406143","article-title":"Trends in opioid analgesic abuse and mortality in the United States","volume":"372","author":"Dart","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.cld.2020.06.001_bib66","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/hep.29572","article-title":"The rise of the opioid epidemic and hepatitis C\u2013positive organs: a new era in liver transplantation","volume":"67","author":"Gonzalez","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2020.06.001_bib67","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2020.06.001_bib68","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.drugalcdep.2016.10.021","article-title":"Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents","volume":"169","author":"Tsui","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.cld.2020.06.001_bib69","first-page":"132","article-title":"Diabetes, HBV infection and smoking are independent risk factors for developing hepatocellular carcinoma on non-fibrotic liver in the NoFLIC French multicenter case-control study","volume":"62","author":"Blanc","year":"2015","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.cld.2020.06.001_bib70","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nrc2191","article-title":"Molecular mechanisms of alcohol-mediated carcinogenesis","volume":"7","author":"Seitz","year":"2007","journal-title":"Nat Rev Cancer"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326120300507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326120300507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:55:40Z","timestamp":1761069340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326120300507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1089326120300507"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2020.06.001","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Changing Global Epidemiology of Hepatocellular Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2020.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}